Vilazodone (brand name Viibryd) is a prescription antidepressant approved to treat major depressive disorder (MDD) in adults. It is the only FDA-approved use for this medication. Unlike older antidepressants that work in a single way, vilazodone combines two mechanisms: it blocks the reabsorption of serotonin (like traditional SSRIs) while also partially activating a specific serotonin receptor called 5-HT1A. This dual action is what sets it apart from medications like sertraline or escitalopram.
How Vilazodone Works
Serotonin is a chemical messenger in the brain that plays a central role in mood regulation. When nerve cells release serotonin, they normally reabsorb some of it. Vilazodone blocks that reabsorption, leaving more serotonin available in the brain. It does this with very high precision, binding tightly to the serotonin reuptake site without affecting dopamine or norepinephrine transporters.
The second part of its mechanism is the partial activation of 5-HT1A receptors. “Partial agonist” means it stimulates these receptors, but not as strongly as a full activator would. The FDA notes that the exact role this plays in relieving depression isn’t fully understood, but the combination is thought to enhance serotonin signaling in the central nervous system more effectively than reuptake blockade alone.
Off-Label Uses
Some prescribers use vilazodone for conditions beyond depression, though the evidence supporting these uses varies considerably.
For generalized anxiety disorder (GAD), three industry-sponsored clinical trials found that vilazodone at 20 to 40 mg per day improved anxiety scores compared to placebo. The 40 mg dose consistently outperformed placebo, while the 20 mg dose showed mixed results. However, a meta-analysis found the overall effect size was small, and improvements in day-to-day functioning were less impressive than the anxiety score changes suggested. It is not considered a first-line treatment for GAD.
For social anxiety disorder, one small pilot study showed greater improvement than placebo over 12 weeks, but the evidence is too limited to draw firm conclusions. For obsessive-compulsive disorder, there are no published clinical trials despite a theoretical reason to think vilazodone’s 5-HT1A activity might help. Its use for OCD is not evidence-based at this time.
Starting and Adjusting the Dose
Vilazodone follows a gradual titration schedule. You start at 10 mg once daily for the first week, then increase to 20 mg once daily. After at least another week, your prescriber may raise the dose to 40 mg if needed. The target range is 20 to 40 mg per day.
One detail that genuinely matters for effectiveness: vilazodone must be taken with food. When taken on an empty stomach, your body absorbs dramatically less of the drug. Studies show that eating a meal increases the amount of vilazodone reaching your bloodstream by 64 to 85 percent, and peak blood levels roughly double. Skipping meals while taking it can significantly reduce how well the medication works.
Common Side Effects
Digestive symptoms are the most frequent side effects, and they’re noticeably more common than with placebo. In clinical trials, about 28% of people taking vilazodone experienced diarrhea (compared to roughly 10% on placebo), and about 23% had nausea (compared to 7% on placebo). Vomiting occurred in about 5% of patients.
The good news is that these symptoms tend to be front-loaded. Most nausea and diarrhea appeared during the first two weeks, when the dose is being gradually increased. The median duration of nausea was 5 days, and for diarrhea, 8 days. For most people, these effects are temporary and manageable. It’s worth noting that vomiting can reduce absorption of the medication by 22 to 30 percent, so if nausea with vomiting is persistent during the titration period, your prescriber may need to adjust the plan.
Weight and Sexual Side Effects
Two side effects that matter most to many people considering an antidepressant are weight gain and sexual dysfunction. Vilazodone performs relatively well on both counts.
In clinical trials, the average weight change was essentially zero: patients on vilazodone gained 0.16 kg on average, compared to 0.18 kg on placebo. That’s statistically indistinguishable. A small percentage of patients (about 6.5%) did experience weight increases of 10% or more over the course of longer studies, but this was not dramatically different from what’s seen with many other medications. Metabolic markers like blood sugar and cholesterol showed no meaningful differences between vilazodone and placebo groups.
Vilazodone is often highlighted for its potentially lower rate of sexual side effects compared to traditional SSRIs. The available evidence suggests that when sexual side effects do occur, they tend to be mild enough that they don’t drive people to stop taking the medication. That said, no head-to-head trials have directly compared vilazodone’s sexual side effect profile against other antidepressants, so the advantage, while plausible given its mechanism, hasn’t been definitively proven.
Stopping Vilazodone Safely
Like other serotonin-based antidepressants, vilazodone should not be stopped abruptly. Sudden discontinuation can trigger withdrawal symptoms including dizziness, nausea, irritability, anxiety, insomnia, electric shock-like sensations, sweating, confusion, and headache. In rare cases, more serious symptoms like seizures can occur.
The recommended tapering schedule is straightforward. If you’re on 40 mg, you drop to 20 mg for four days, then to 10 mg for three days before stopping. If you’re on 20 mg, you reduce to 10 mg for seven days before discontinuing. This gradual step-down helps your brain adjust to lower serotonin levels and minimizes the risk of uncomfortable withdrawal effects.
Who Should Not Take Vilazodone
Vilazodone is approved only for adults. It is not approved for use in children or adolescents. Like all antidepressants, it carries an FDA boxed warning about increased risk of suicidal thoughts and behavior in younger patients, which is one reason pediatric use has not been approved. Adults starting any antidepressant, particularly those under 25, are typically monitored closely during the first several weeks of treatment for changes in mood or behavior.
Vilazodone should not be taken alongside monoamine oxidase inhibitors (MAOIs) or other medications that significantly increase serotonin levels, due to the risk of serotonin syndrome, a potentially dangerous condition caused by excessive serotonin activity in the body.